Vertex Pharmaceuticals, from Boston, MA, led in using smart drug design, a step away from mix-and-match chemistry, pioneering biotech.
Image Credits: Bloomberg
Vertex Pharma, with a 1.75% stake, excels in cystic fibrosis treatment. Investors seek diversification for sustained growth beyond its billion-dollar CF success.
Image Credits: FX Empire
Vertex faced setbacks with AATD treatments in 2020-21, causing a 35% stock drop, signaling challenges in diversifying beyond CF.
Image Credits: Unsplash
Vertex and CRISPR Therapeutics made big strides treating blood disorders. Progress in their program is significant and noteworthy.
Image Credits: Technology Networks
Vertex and CRISPR Therapeutics got the green light for Casgevy, a sickle cell treatment. This win signals Vertex's success beyond cystic fibrosis.
Image Credits: Unsplash
Vertex is set to launch Casgevy now, with nine approved treatment centers nationwide. Approximately 16,000 eligible patients could benefit from this gene-editing product.
Image Credits: Unsplash
Vertex and CRISPR Therapeutics face slow revenue growth due to extended treatment periods. Goldman Sachs predicts Casgevy's peak revenue at $3.9 billion.
Image Credits: Unsplash
Vertex pays CRISPR Therapeutics $200 million after FDA approval, keeping 60% of product profits per the profit-sharing deal.
Image Credits: Unsplash
Vertex might introduce new products, like a pain management treatment. They're finishing a crucial trial, with results expected early next year.
Image Credits: Fierce Pharma